Jenny Harry
Non-Executive Director
Healthcare
 Solvanix...
Australia
Biography
Dr Harry is a non-executive director of Solvanix Pty Ltd. She is also Chair of QUT Enterprise Holdings Pty Ltd and holds non-executive directorships on the QUT bluebox and QUT Creative Industries boards. She brings experience in leadership, commercialisation strategy, risk assessment and mitigation, and high level stakeholder engagement. Jenny is an accomplished Managing Director of small listed and unlisted companies with experience in structuring effective organisations, strategic planning, business development, capital raising and commercialising technologies. She is currently CEO of Ondek Pty Ltd, a life sciences company that is using a natural occurring gut bacterium to develop novel therapies for allergy. Previously, Jenny was the Managing Director of ASX-listed Tyrian Diagnostics, where she led the transformation of the company from biomarker R&D to product development and commercialisation of the company’s first diagnostic product. Jenny has a PhD in developmental biology, completed the General Manager Program at Harvard Business School in 2006 and is a graduate of the Australian Institute of Company Directors.
Research Interest
Dr Harry is a non-executive director of Solvanix Pty Ltd. She is also Chair of QUT Enterprise Holdings Pty Ltd and holds non-executive directorships on the QUT bluebox and QUT Creative Industries boards. She brings experience in leadership, commercialisation strategy, risk assessment and mitigation, and high level stakeholder engagement. Jenny is an accomplished Managing Director of small listed and unlisted companies with experience in structuring effective organisations, strategic planning, business development, capital raising and commercialising technologies. She is currently CEO of Ondek Pty Ltd, a life sciences company that is using a natural occurring gut bacterium to develop novel therapies for allergy. Previously, Jenny was the Managing Director of ASX-listed Tyrian Diagnostics, where she led the transformation of the company from biomarker R&D to product development and commercialisation of the company’s first diagnostic product. Jenny has a PhD in developmental biology, completed the General Manager Program at Harvard Business School in 2006 and is a graduate of the Australian Institute of Company Directors.
